Signal Detection and Regulatory Expectations

This two-day programme will give you a comprehensive review of signal detection and regulatory expectations including the new updated Signal Module IX and Eudravigilance quantitative signal requirement

25-26 Nov 2019

& 5-6 May 2020 , 2-3 Nov 2020

GBP 1,499
EUR 2,099
USD 2,338

Book now

Course overview

Including the updated Signal Module IX and EudraVigilance quantitative signal requirement

Increasingly, the most common critical findings in regulatory inspections are being given for signal detection and management – so the need to identify potential signals and risks in patients has never been greater. The protection of patients through robust and clear methodologies for signal detection amidst the ever-increasing regulations requires companies to have trained and competent staff to perform such activities. This course will provide a detailed overview of all aspects of safety reviews and signal detection within a company and will cover signal evaluation for both innovator and generic products under the newly revised Module IX signal management and quantitative assessments.

Benefits of attending:

  • Clarify the EU regulatory requirements for signal detection
  • Learn to use the EudraVigilance quantitative signal tool
  • Understand the safety review cycle and the safety review meeting and process
  • Understand EVDAS functionalities and outputs
  • Discuss safety communication – the CCSI/SCSI and labelling
  • Gain a better understanding of risk-benefit analysis – benefit-risk assessments and benefit-risk outcomes

Who should attend

This course will be of interest to all those working in drug safety/pharmacovigilance as well as regulatory personnel responsible for amending the labelling for products and for the production of the CCSI/DCSI.

Programme - Day one

An introduction to safety signals

  • History of safety signals
  • The nature of safety signals
  • The definition of safety signals
  • Safety sources for signal detection

Causality and signal detection

  • Causality assessments for signal review
  • Data quality in safety assessments
  • Causality versus incidence (DMEs and IMEs)
  • Generic and innovator products

The safety review meeting and process

  • Setting up a safety review
  • Risk determinations for safety review signal trackers
  • Information and templates
  • Logistical safety and product safety
  • Information from safety reviews

Safety assessments life cycle

  • Pre-clinical safety
  • Clinical safety
  • Class-related safety issues
  • Post-marketing safety
  • Product suspensions/withdrawals

Safety assessments life cycle (continued)

The regulatory requirements for signal detection – Module IX

  • The frequency of safety reviews (risk assessment)
  • The EU and US signal detection requirements
  • Signal detection and benefit-risk assessments
  • The regulators and signals

The signal review cycle

  • Safety profiling
  • Signal detection, validation, confirmation
  • Analysis and prioritisation, assessment
  • Recommendation for action

Programme - Day two

Quantitative and qualitative signal detections

  • Standard MedDRA queries (SMQs) and signal detection
  • ICSRs and case quality
  • Follow-up methodology and regulatory requirements
  • Events of special interest

Signals and their discussion

  • Signals and DSURs
  • Signals and PSURs/PBRERs
  • Signals and risk management plans/REMs and minimisation
  • Signals and labelling

Safety communication

  • The CCSI/DCSI and labelling
  • Triaging for safety amendments
  • Emerging safety issues
  • Urgent safety restrictions
  • Product suspension and withdrawal

Quantitative signal analysis

  • Signal detection methodologies
  • Background – why quantitative signal detection?
  • Measures of disproportionality (PRR, ROR, MGPS, BCPNN)
  • Regulatory and industry activity (including EudraVigilance)

EVDAS and the EU

  • The PRAC and signals
  • The EVDAS system
  • Signals arising from EVDAS

Risk-benefit analysis

  • Calculating the extent of benefit by indication
  • Identifying significant product risks
  • Benefit-risk assessments
  • Benefit-risk outcomes

Presenter

Graeme Ladds

Graeme Ladds, Director of PharSafer, has over 30 years’ experience working in the pharmaceutical industry. Having started his career at Ashbourne Pharmaceuticals in 1989 as Head of Drug Safety & Medical Information, he went on to become Head of Global Pharmacovigilance at Shire Pharmaceuticals. He then set up his consultancy and specialist CRO company, PharSafer Associates Ltd, where he has been involved in establishing pharmacovigilance in companies, performing audits across Europe and the USA, SOP writing, acting as QP for companies, and helping with regulatory inspections.

Book now

25-26 Nov 2019
25-26 Nov 2019 Rembrandt Hotel, London GBP 1,499.00
EUR 2,099.00
USD 2,338.00
+ VAT @ 20.00%
Enrol now
Limited places
5-6 May 2020
5-6 May 2020 Rembrandt Hotel, London GBP 1,499.00
EUR 2,099.00
USD 2,338.00
+ VAT @ 20.00%
Enrol now
2-3 Nov 2020
2-3 Nov 2020 Rembrandt Hotel, London GBP 1,499.00
EUR 2,099.00
USD 2,338.00
+ VAT @ 20.00%
Enrol now

You may also be interested in

Previous customers include...

  • Alfasigma S.p.A.
  • Aspen Pharma Trading Ltd
  • AstraZeneca
  • Di Renzo SRL
  • Eisai Europe Limited
  • Ewopharma International, s.r.o.
  • FERRER
  • GE Healthcare AS
  • Genethics Regulatory Services
  • Grupo Ferrer Interancional
  • Grupo Ferrer Internacional SA
  • Intervet International BV MSD Animal Health
  • LEO Pharma A/S
  • Merck Selbstmedikation GmbH
  • Norgine
  • OY Medfiles LTD
  • Pharmacovigilance Matters Limited
  • Pharmvit Ltd
  • Pierre Fabre
  • PROGE MEDICA SRL
  • Redline Pharmacovigilance Ltd
  • Regulis Consulting Ltd
  • Research and Markets
  • Roche Products Ltd - WELWYN GARDEN CITY, Hertfordshire
  • Santen Oy
  • STALLERGENES SAS
  • Statens Serum Institut
  • Transgene S.A.
  • Veterinary Medicines Directorate
  • Zoetis Belgium S.A.

The speaker was well-experienced with in-depth knowledge in practical issues related to signals. Great show.

Torsten Schlüter, Senior PV Manager, CHEPLAPHARM Arzneimittel GmbH

Excellent course, highly recommended and the topics were well suited for the particular area

Anna Fernandez-Saranillo, Drug Safety Specialist, Roche Products

Very good overall with interesting course content, well presented with thorough course notes and an engaging speaker.

Kari Karolia, Senior Pharmacovigilance Associate, GW Pharmaceuticals

It was a good course, very informative with a very proficient speaker. The course content focussed on the concept of signals that then become risks. The presentation was very good and covered the topics well.

Adam Bedford, Pharmacovigilance Associate, GW Pharma

A very useful course

Elisabetta Parretta, Drug Safety Officer, Faes Farma

A very useful course

Elisabetta Parretta, Drug Safety Officer, Faes Farma

It's comprehensive course and could help the PV workers in companies more than the ones who work in authorities.

Hajer Mohammed AlSaleh, Pharmacist , Saudi Food and Drug Authority

Graeme is an expert on signal detection and has a lot of practical examples to animate the substance matter. Content was of high quality.

Antti Miikki, Pharmacovigilance Specialist, Santen Oy

The slides were a bit overloaded. Other than that, just great.

Katja Funke, Head of Safety Risk Management, Merck Selbstmedikation GmbH

Very good

Chiara Bertarello, Deputy of QPPV, PROGE MEDICA SRL

Excellent throughout

Penuşa Stroia, Head of Regulatory Affairs , Genethics Regulatory Services

Very lively and complete

Violaine de la Tourette, Safety Officer Associate, Pierre Fabre